Across 17 double-blind randomized trials encompassing 13,461 adults with hypertension, triple antihypertensive drug (AHTD) combinations reduced systolic blood pressure by 26.9 mmHg versus 21.7 mmHg for dual therapy — a mean difference of 5.4 mmHg (95% CI: 4.7–6.2). BP control rates were 60% versus 47% (RR=1.34). Crucially, adding a third drug to submaximal dual therapy yielded a 7.5 mmHg additional reduction, versus only 3.6 mmHg when dual therapy was already at maximal doses. Adverse-event-driven withdrawal was modestly elevated: 4% versus 3% (RR=1.5).
This meta-analysis arrives as hypertension management guidelines increasingly debate polypill strategies and combination intensification. The 5.4 mmHg systolic advantage is clinically meaningful — epidemiological data suggest each 5 mmHg reduction correlates with roughly 10% lower stroke risk and 7% lower coronary heart disease risk. The finding that adding a third agent to submaximal dual therapy nearly doubles the benefit versus adding it at maximal doses carries real prescribing logic: it supports earlier combination intensification rather than dose-maximizing a two-drug regimen. The modest 1.5-fold withdrawal risk, while statistically significant, translates to just one additional dropout per 100 patients — a manageable safety signal. Limitations include short trial durations (≥3 weeks), potential heterogeneity across drug classes, and the absence of hard cardiovascular outcomes data. As a preprint not yet peer-reviewed, these effect sizes and safety conclusions should be treated as preliminary until full independent scrutiny is complete. Overall, this represents confirmatory, practically useful evidence supporting earlier triple combination use.
